Monday, October 19, 2026

BTC $82,423 ▲ 0.51%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

ADA$0.219−0.98%ETH$2,426+0.78%LINK$12.09+0.53%SOL$105.01+0.99%BTC$82,423+0.51%XRP$1.31+0.07%S&P 5007,659−1.09%Nasdaq26,140−2.14%Dow52,002−0.34%RUT2,721−1.66%TNX5.10%+0.18%TYX5.44%+0.13%FVX4.90%+0.00%IRX4.07%−0.44%VIX18.64−6.75%GOLD$4,188.60+0.18%SILVER$57.71+0.71%OIL$98.45−0.58%DXY101.94+0.10%NVDA$214.13−1.43%AAPL$343.46+0.43%TSLA$354.72−2.13%META$709.33−3.72%MSFT$529.05−1.93%AMZN$250.00−1.87%GOOGL$340.59−2.47%Fear & Greed59 — GreedADA$0.219−0.98%ETH$2,426+0.78%LINK$12.09+0.53%SOL$105.01+0.99%BTC$82,423+0.51%XRP$1.31+0.07%S&P 5007,659−1.09%Nasdaq26,140−2.14%Dow52,002−0.34%RUT2,721−1.66%TNX5.10%+0.18%TYX5.44%+0.13%FVX4.90%+0.00%IRX4.07%−0.44%VIX18.64−6.75%GOLD$4,188.60+0.18%SILVER$57.71+0.71%OIL$98.45−0.58%DXY101.94+0.10%NVDA$214.13−1.43%AAPL$343.46+0.43%TSLA$354.72−2.13%META$709.33−3.72%MSFT$529.05−1.93%AMZN$250.00−1.87%GOOGL$340.59−2.47%Fear & Greed59 — Greed

Tag

mrna

3 articles

U.S. Equities7d ago

Moderna at $225: Melanoma Data and NIH Backing Justify Bull Case

Moderna has surged 600 percent in 2026 on melanoma vaccine efficacy and reported NIH support for personalized cancer vaccines, with analysts modeling $225 as fair value.

U.S. Equities56d ago

Moderna Surges 177% on Melanoma Vaccine Win; Wall Street Raises Targets

Moderna stock soared on positive Phase 3 results for its personalized melanoma vaccine with Merck, prompting Morgan Stanley to raise its price target to $89 from $39.

U.S. Equities58d ago

Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk

Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.